Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038002 (splenomegaly)
 9,873 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Intraperitoneal administration of Corynebacterium parvum to BALB/c, C57Bl/6 or C3H/HeJ mice lead to the induction of elevated levels of neutral proteinase activity (125I-caseinolytic activity) similar to those observed previously in animals bearing the BCL1 leukemia or the B16-F10 melanoma. Enhanced activity reached a peak at 7-14 days postinjection of the C. parvum and then gradually returned to normal levels by 20-25 days postinjection. Increased plasma proteinase activity could be induced by C. parvum whole cells or the pyridine extract residue of C. parvum but not by BCG or the pyridine extract of C. parvum. BCG did not interfere with the induction of elevated levels of activity by C. parvum. Splenectomized animals responded the same as normal mice indicating that the splenomegaly accompanying the onset of increased plasma proteinase activity was not responsible for the changes. Administration of C. parvum via a subcutaneous site rather than intraperitoneally failed to induce systemic changes in proteinase activity while still inducing splenomegaly. Treatment of animals with C. parvum before or after transplantation of the BCL1 leukemia or the B16-F10 melanoma failed to alter the course of the disease or enhance the increased proteinase activity of plasma over that observed in plasma from animals bearing tumors alone. These observations support the hypothesis that the induction of disturbances in plasma proteinase activity in tumor-bearing animals is due to alterations in host systems and that C. parvum, in contrast to BCG, contains components which can mimic the effect of some tumors on host systems.
 ...
PMID:Corynebacterium parvum, but not BCG, induces elevations in plasma proteinase activity similar to those observed in tumor-bearing mice. 329 43

C57B1/6 mice bearing the B16-F1 melanoma, an invasive variant (BL6) or a highly 'metastatic' variant (B16-F10) were found to develop elevated levels (200-300% of control) of neutral proteinase activity in their plasma during the progression of the disease. The magnitude of the level of proteinase activity detected was not dependent on tumor burden. Similar elevations in activity were detected with all 3 variants when they were transplanted either subcutaneously or intraperitoneally. However, transplantation of the B16-F10 line to the anterior chamber of the eye did not induce elevated plasma proteinase activity. Animals bearing intraocular tumors developed splenomegaly and lived the same length of time as animals bearing intraperitoneal or subcutaneous tumors. The development of increased levels of activity appeared to occur equally in male and female mice and was not dependent on the presence of a spleen, which undergoes enlargement during the disease process. These various lines of evidence support the hypothesis that the elevated level of plasma proteinase activity observed in melanoma-bearing mice is regulated by the host.
 ...
PMID:Evidence that the elevated levels of proteinase activity in the plasma of melanoma-bearing mice may be of host origin. 351 6